A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants
Condition: Schizophrenia, Cerebellar Ataxia
MeSH terms: Ataxia; Cerebellar Ataxia; Schizophrenia
Intervention: TAK-831 Oral Suspension; TAK-831 Placebo; TAK-831 Tablet
Intervention description: TAK-831 oral suspension.; TAK-831 placebo-matching oral suspension.; TAK-831 tablet.
Phase: Phase 1
Study type: Interventional
Primary purpose: Other
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 110.0
Sex: All
Minimum age: 18 Years
Maximum age: 55 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Drug therapy

Summary:

      The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK)
      of single and multiple rising doses of TAK-831 in healthy participants.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Should be capable of understanding and complying with protocol requirements.

          2. The participant or, when applicable, the participant's legally acceptable
             representative signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

          3. Healthy male or female aged between 18 to 55 years- Weighing at least 45 kilogram (kg)
             and has a body mass index (BMI) from 18.0 to 30.0 kilogram per square meter (kg/m^2).

          4. Male participant who is nonsterilized and sexually active with a female partner of
             childbearing potential agrees to use adequate contraception from signing of informed
             consent throughout the duration of the study and for 12 weeks after last dose.

          5. Female participant with no childbearing potential, defined as a participant that has
             been surgically sterilized (hysterectomy, bilateral oophorectomy or tubal ligation) or
             who is post menopausal (defined as continuous amenorrhea of at least 2 years and
             follicle-stimulating hormone [FSH] greater than [>] 40 international units per liter
             [IU/L]).

        Exclusion Criteria:

          1. Received any investigational compound within 3 months prior to randomization.

          2. Is an immediate family member, study site employee, or is in a dependent relationship
             with a study site employee who is involved in the conduct of this study (example,
             spouse, parent, child, sibling) or may consent under duress.

          3. Has uncontrolled, clinically significant neurological (including seizure disorders),
             cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic,
             immunologic, endocrine disease, or psychiatric disorder, or other abnormality.

          4. Has a known hypersensitivity to any component of the formulation of TAK-831.

          5. Female participant is of childbearing potential.

          6. Has a positive urine drug result for drugs of abuse (defined as any illicit drug use)
             at Screening or Check-in.

          7. History of drug abuse (defined as any illicit drug use) or a history of alcohol abuse
             within 1 year prior to the Screening visit or is unwilling to agree to abstain from
             alcohol and drugs throughout the study. One unit is equivalent to a half-pint of beer
             or 1 single measure of spirits or 1 small glass of wine.

          8. Has taken any excluded medication, supplements, or food products during the time
             periods listed in the excluded medications and dietary products.

          9. Female participant is pregnant or lactating or intending to become pregnant before,
             during, or within 1 month after participating in this study; or intending to donate
             ova during such time period.

         10. Male participant intending to donate sperm during the course of this study or for 12
             weeks after the last dose of study medication.

         11. Has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic
             disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy,
             asthma, hypoxemia, hypertension, seizures, or allergic skin rash.

         12. Has a QT interval with Fridericia's correction method (QTcF) >450 millisecond (msec)
             (males) or >470 msec (females) or PR outside the range of 120 to 220 msec, confirmed
             with one repeat testing, at the screening visit or check-in (Day -2).

         13. Has current or recent (within 6 months) gastrointestinal disease that would be
             expected to influence the absorption of drugs (that is, a history of malabsorption,
             esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent [more than once
             per week] occurrence of heartburn, or any surgical intervention.

         14. Has a history of cancer, except basal cell carcinoma which has been in remission for
             at least 5 years prior to Day 1.

         15. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus
             (HCV) antibody, or human immunodeficiency virus (HIV) antibody/antigen at Screening.

         16. Has used nicotine-containing products (including but not limited to cigarettes, pipes,
             cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to
             Check-in. Cotinine test is positive at Screening or Check-in.

         17. Has poor peripheral venous access.

         18. Has donated or lost 450 milliliter (mL) or more of his or her blood volume (including
             plasmapheresis), or had a transfusion of any blood product within 45 days prior to
             first dose of medication.

         19. Has a Screening or Check-in abnormal (clinically significant) electrocardiogram (ECG).
             Entry of any participant with an abnormal (not clinically significant) ECG must be
             approved, and documented by signature by the principal investigator or designee.

         20. Has a supine blood pressure outside the ranges of 90 to 140 millimeter of mercury (mm
             Hg) for systolic and 50 to 90 mm Hg for diastolic, confirmed on repeat testing within
             a maximum of 30 minutes, at the Screening Visit or Check-in.

         21. Has a resting heart rate outside the range 40 to 100 bpm confirmed on repeat testing
             within a maximum of 30 minutes, at the Screening Visit or Check-in.

         22. Has abnormal Screening or check-in laboratory values that suggest a clinically
             significant underlying disease or participant with the following lab abnormalities:
             Alanine transaminase (ALT) and/or aspartate aminotransferase (AST) >1.5 the upper
             limits of normal.

         23. Has a risk of suicide according to the Investigator's clinical judgment (example, per
             The Columbia Suicide Severity Rating Scale [C-SSRS]), or has scored "yes" on item 4 or
             item 5 of the Suicidal Ideation section of the C-SSRS, if this ideation occurred in
             the past 6 months, or "yes" on any item of the Suicidal Behavior section, except for
             the "Non-Suicidal Self-Injurious Behavior", if this behaviour occurred in the past 2
             years.

         24. Has received TAK-831 in a previous clinical study.

         25. Participant is vegan or vegetarian (Part 4 only - food effect).